Recent publications
Background: The Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) serves as a comprehensive
clinical assessment tool for non-motor symptoms in Parkinson’s disease (PD)
Objectives: This study aims to validate the Portuguese version of the MDS-NMS, addressing the critical need for
culturally adapted rating scales in Portuguese-speaking populations.
Methods: This multicenter, cross-sectional study engaged native Portuguese-speaking PD patients from 16
Movement Disorders Centers across Portugal and Brazil. We conducted a meticulous translation process into
Portuguese, including forward-backward translation and cognitive pretesting. Confirmatory factor analysis (CFA)
and exploratory factor analysis (EFA) were conducted to evaluate the psychometric properties and structural
validity of the Portuguese version in comparison to the original English version. Tertiary analyses assessed the
acceptability and reliability of domain scores within the cohort.
Results: The scale was administered to 386 PD Portuguese-speaking patients. CFA, conducted with a final sample
of 303 participants, confirmed that the Portuguese version maintained a factor structure consistent with the
English original, with Comparative Fit Index (CFI) values meeting or exceeding the 0.90 threshold across all
subscales. High CFI values in domains such as Depression, Psychosis, and Cognition underscored the robustness
of the translation. EFA revealed generally strong item-factor relationships, although domains like Gastrointestinal and Non-Motor Fluctuations exhibited more complex structures. Reliability analyses demonstrated strong
internal consistency, with Cronbach’s α ranging from 0.50 to 0.86 across domains, further corroborated by
McDonald’s ω and Greatest Lower Bound values.
Conclusions: The Portuguese version of the MDS-NMS demonstrates psychometric properties and structural
validity that closely aligns with the original version.
Importance
Poor cardiometabolic health is a risk factor associated with cognitive impairment in later life, but it remains unclear whether cardiometabolic trajectories can serve as early markers associated with dementia.
Objective
To compare cardiometabolic trajectories that precede dementia diagnosis with those among individuals without dementia.
Design, Setting, and Participants
This case-control study analyzed a sample drawn from community-dwelling participants in the Aspirin in Reducing Events in the Elderly (ASPREE) study. Recruitment through primary care physicians occurred between March 2010 and December 2014, with participants followed up for a maximum of 11 years. Dementia cases were matched on sociodemographic characteristics and time of diagnosis to dementia-free controls. Data analysis was performed between February and June 2024.
Exposures
Body mass index (BMI), waist circumference, systolic and diastolic blood pressure, glucose levels, high- and low-density lipoprotein (HDL and LDL) and total cholesterol levels, and triglyceride levels were measured repeatedly between 2010 and 2022.
Main Outcomes and Measures
Dementia ( Diagnostic and Statistical Manual of Mental Disorders [ Fourth Edition ] criteria) was adjudicated by an international expert panel.
Results
Among 5390 participants (mean [SD] age, 76.9 [4.8] years; 2915 women [54.1%]), there were 2655 individuals (49.3%) with less than 12 years of education. The study included 1078 dementia cases and 4312 controls. Up to a decade before diagnosis, dementia cases compared with controls had lower BMI for all years from −7 years (marginal estimate, 27.52 [95% CI, 27.24 to 27.79] vs 28.00 [95% CI, 27.86 to 28.14]; contrast P = 002) to 0 years (marginal estimate, 26.09 [95% CI, 25.81 to 26.36] vs 27.22 [95% CI, 27.09 to 27.36]; contrast P < .001) and lower waist circumference for all years from −10 years (marginal estimate, 95.45 cm [95% CI, 94.33 to 96.57 cm] vs 97.35 cm [95% CI, 96.79 to 97.92 cm]; contrast P = .003) to 0 years (marginal estimate, 93.90 [95% CI, 93.15 cm to 94.64 cm] vs 96.67 cm [95% CI, 96.30 to 97.05 cm]; contrast P < .001); cases also had a faster decline in BMI (linear change β, −0.13 [95% CI, −0.19 to −0.08]) and waist circumference (linear change β, −0.30 cm [95% CI, −0.51 to −0.08 cm]). Compared with controls, cases generally had higher HDL levels, in particular from 5 years (marginal estimate, 62.57 mg/dL [95% CI, 61.59 to 63.56 mg/dL] vs 60.84 mg/dL [95% CI, 60.35 to 61.34 mg/dL]; contrast P = .002) to 3 years (marginal estimate, 62.78 mg/dL [95% CI, 61.82 to 63.74 mg/dL] vs 61.08 mg/dL [95% CI, 60.60 to 61.56 mg/dL]; contrast P = .002) before dementia but with a decline in levels just before diagnosis (linear change β, −0.47 mg/dL [95% CI, −0.86 to −0.07 mg/dL]). Dementia cases had lower systolic blood pressure and triglyceride levels in the decade before diagnosis and higher LDL and total cholesterol levels, but these were not significantly different from controls.
Conclusions and Relevance
In this study of older individuals, decline in BMI, waist circumference, and HDL occurred up to a decade before dementia diagnosis. These findings provide insights into cardiometabolic changes preceding dementia and the potential for early monitoring and intervention.
Objective
Robust research has established that preexisting physical and mental health conditions increase risk for adverse psychiatric outcomes after disasters. However, it is unclear if increased risk is independent of disaster exposure, and most studies have relied on retrospective reports of pre-disaster functioning.
Methods
In a pre-post sample of high-risk Puerto Rican adults (N = 361) who experienced Hurricanes Irma and Maria, we assessed: 1) whether indicators of pre-disaster depression and physical health conditions were associated with posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) symptoms; and 2) whether the effects of pre-disaster depression and physical health conditions on PTSD and MDD symptoms were indirect via disaster exposure or had exacerbated the effects of disaster exposure on PTSD and MDD symptoms.
Results
Pre-disaster depression and physical health problems were significantly associated with higher post-disaster MDD symptoms (B = 1.50, SE = 0.36, p < .001, and B = 0.21; SE = 0.09, P = 0.016), but not PTSD symptoms. Indirect effects of pre-disaster depression and physical health symptoms via disaster exposure were non-significant, and neither moderated the association of disaster exposure on PTSD and MDD symptoms.
Conclusions
Research is needed to understand other pathways through which pre-disaster health conditions predict post-disaster mental health.
Objective: The current intense period of drug development for fragile X syndrome (FXS) and other neurodevelopmental disorders (NDDs) indications has highlighted the importance of behavioral outcome measures with strong psychometric properties and specifically content validity. The Aberrant Behavior Checklist-Community Edition (ABC-C), which has successfully been applied to autism spectrum disorder drug trials, has been revised for FXS (ABCFX) and is widely used for both clinical and research purposes. Despite its strong psychometric validation, the ABCFX and its parent measure have not been subjected to qualitative content validity evaluations. The present study intended to fill this gap. Methods: Using two surveys administered sequentially and developed with guidance and review from the Food and Drug Administration (FDA), we asked 10 clinicians experienced in FXS and related NDDs to determine the adequacy of the ABCFX for assessing its behavioral constructs, its relevance to FXS, and its potential for detecting response to interventions. Various descriptive statistic parameters and ad hoc metrics were used to analyze categorical and Likert-like scale responses. Results: Experts considered that most items and all six ABCFX subscales indeed evaluated their explicit or implicit behavioral constructs. However, item and subscale specificity were relatively low (∼25%-30%). Relevance of items of the Hyperactivity subscale was relatively high while low for many items of the Socially Unresponsive/Lethargic subscale. These items were also considered of low responsiveness potential. Irritability, Hyperactivity, Stereotypy, and Social Avoidance were the subscales with the strongest profiles, although the experts estimated that Stereotypy items may not be that responsive to treatment. A novel Anxiety construct, representing mainly recently reported observable behaviors, contributed mainly by Irritability items, emerged as a potential measure. Conclusions: The present study demonstrated the overall adequacy of the ABCFX for its behavioral constructs, its relevance to FXS, and its potential for detecting response to treatment. It also showed that anxiety, a distinctive feature of FXS and other genetic NDDs, can also be measured by the ABCFX. These findings can help with the implementation and interpretation of the ABCFX, as well as with potential improvements to the measure in FXS and other NDDs.
Background
The development of posttraumatic osteoarthritis (PTOA) of the knee after anterior cruciate ligament (ACL) reconstruction (ACLR) leads to additional morbidity in adults.
Purpose
To determine the 5-year incidence of and risk factors for PTOA diagnoses after primary ACLR in pediatric patients.
Study Design
Case control study, Level of evidence, 3.
Methods
A United States-based insurance database was used to identify patients aged ≤16 years who underwent primary ACLR from 2010 to 2019 and had at least 5 years of follow-up data. Patients with multiligament knee injuries, tibial eminence avulsion fractures, congenital/syndromic ACL absence syndrome, juvenile idiopathic arthritis, previous knee osteoarthritis or PTOA diagnoses, or previous knee injuries/surgeries were excluded. Demographic factors and concomitant meniscal and cartilage procedures at the time of primary ACLR were recorded. Delayed ACLR was defined as ≥3 months between initial ACL injury diagnosis and ACLR. We also recorded the presence of subsequent motion restoration reoperations, including lysis of adhesions and/or manipulation under anesthesia, after primary ACLR but before PTOA diagnosis. Risk factors for PTOA were evaluated using multivariable logistic regression.
Results
Included were 16,935 patients (mean age at surgery, 15.1 ± 1.2 years; 62% women). PTOA was diagnosed in 267 patients (1.6%) within 5 years after ACLR; 148 of these patients (55.4%) were diagnosed within 2 years after ACLR. Independent risk factors associated with PTOA diagnosis included subsequent motion restoration procedures (odds ratio [OR], 5.03 [95% CI, 3.31-8.25]; P < .001), age ≥12 years at the time of ACLR (OR, 4.82 [95% CI, 1.54-29.20]; P = .027), delayed ACLR (OR, 1.87 [95% CI, 1.43-2.43]; P < .001), obesity (OR, 1.40 [95% CI, 1.01-1.94]; P = .046), and male sex (OR, 1.36 [95% CI, 1.06-1.74]; P = .015). Performing concomitant partial meniscectomy, meniscus repair, and cartilage restoration at the time of ACLR was not significantly associated with PTOA.
Conclusion
The incidence of PTOA diagnoses was low within 5 years after primary ACLR in patients ≤16 years old with no subsequent cartilage, meniscus, and/or revision ligament procedures. The need for subsequent motion restoration procedures, age ≥12 years at the time of ACLR, delayed ACLR, obesity, and male sex were significant risk factors associated with a PTOA diagnosis.
Background and Objectives: Family medicine implemented program signals and geographic and setting preferences in the 2023–2024 residency application cycle. We performed a qualitative study with the following aims: (a) describe residency program experiences with implementation of signaling and preferences; and (b) identify opportunities for applicants, advisors, residency leadership, and policymakers to optimize these two programs. Methods: This qualitative study used the RE-AIM framework (reach, effectiveness, adoption, implementation, and maintenance) to guide interviews of family medicine program faculty from the Midwest United States between January and April 2024. We analyzed data using a thematic analysis. Results: We interviewed 21 faculty members. About half of respondents somewhat or strongly agreed that program signals (10, 48%) and geographic and setting preferences (11, 52%) added value to the current system. We identified four themes: (1) Faculty adopted signals and preferences strategically to complement their existing application review strategies; (2) Signals were perceived as reducing application volume and burden; (3) Signals did not impact diversity and equity, but geographic preferences may benefit community health; (4) Modifications to signals and preferences are recommended to optimize use in family medicine. Conclusions: Program faculty implemented signals and preferences into holistic review to reduce application review burden. Signals and preferences should support the unique experiences of family medicine residencies and needs for primary care physician workforce development. Future research should focus on refining signals and preferences and their impact on match outcomes and Supplemental Offer and Acceptance Program participation rates.
Background
Recalcitrant adhesive capsulitis, manifesting as persistent pain and continued range of motion deficits after a trial of conservative care, can be managed via lysis of adhesions with associated capsular release. While traditionally performed in the beach-chair position, capsular release performed via a lateral decubitus approach may provide enhanced visualization and the ability to perform a 360° release without iatrogenic injury to the cartilage surfaces.
Indications
Arthroscopic capsular release in the setting of adhesive capsulitis is utilized when conservative strategies, such as physical therapy and/or corticosteroid injections, do not provide pain and range of motion improvement.
Technique Description
Upon induction of general anesthesia, the patient is placed on the operating table in a lateral decubitus position utilizing the arm positioner of choice. The shoulder’s bony landmarks are identified for proper placement of the arthroscopic portals. A standard posterior portal is first established followed by an anterior portal in the rotator interval. Two-portal diagnostic arthroscopy then ensues. The rotator interval is then released, as is the superior capsule, to the 12-o’clock position using electrocautery. Next, a basket scissor is utilized to release the anterior capsule to the 6-o’clock position followed by posterior-superior and posterior-inferior capsular release while viewing anteriorly. Scope instrumentation is withdrawn and the shoulder manipulated, achieving full range of motion.
Results
It is the senior author’s belief that by performing a capsular release via the lateral decubitus approach, better visualization, and access to the anterior, inferior, and posterior glenoid can be achieved for a complete 360° release. Additionally, risk of cerebral hypoperfusion and iatrogenic injury to the cartilage surfaces while instrumenting the joint is diminished. Upon procedure completion, the patient was observed to have gained full forward flexion, external rotation, and internal rotation.
Discussion/Conclusion
Although traditionally approached via a beach-chair approach, capsular release of end-stage adhesive capsulitis via a lateral decubitus approach has shown to facilitate a circumferential view while providing ease of access to the inferior, anterior, and posterior glenoid, thereby substantially and immediately increasing patient range of motion.
Patient Consent Disclosure Statement
The author(s) attests that consent has been obtained from any patient(s) appearing in this publication. If the individual may be identifiable, the author(s) has included a statement of release or other written form of approval from the patient(s) with this submission for publication.
Generative deep learning has emerged as a promising data augmentation technique in recent years. This approach becomes particularly valuable in areas such as motion analysis, where it is challenging to collect substantial amounts of data. The objective of the current study is to introduce a data augmentation strategy that relies on a variational autoencoder to generate synthetic data of kinetic and kinematic variables. The kinematic and kinetic variables consist of hip and knee joint angles and moments, respectively, in both sagittal and frontal plane, and ground reaction forces. Statistical parametric mapping (SPM) did not detect significant differences between real and synthetic data for each of the biomechanical variables considered. To further evaluate the effectiveness of this approach, a long-short term model (LSTM) was trained both only on real data (R) and on the combination of real and synthetic data (R&S); the performance of each of these two trained models was then assessed on real test data unseen during training. The principal findings included achieving comparable results in terms of nRMSE when predicting knee joint moments in the frontal (R&S: 9.86% vs R: 10.72%) and sagittal plane (R&S: 9.21% vs R: 9.75%), and hip joint moments in the frontal (R&S: 16.93% vs R: 16.79%) and sagittal plane (R&S: 13.29% vs R: 14.60%). The main novelty of this study lies in introducing an effective data augmentation approach in motion analysis settings.
Background
Cellular senescence, a hallmark of aging, has been implicated in Alzheimer’s disease (AD) pathogenesis. Cholesterol accumulation is known to drive cellular senescence; however, its underlying mechanisms are not fully understood. ATP-binding cassette transporter A1 (ABCA1) plays an important role in cholesterol homeostasis, and its expression and trafficking are altered in APOE4 and AD models. However, the role of ABCA1 trafficking in cellular senescence associated with APOE4 and AD remains unclear.
Methods
We examined the association between cellular senescence and ABCA1 expression in human postmortem brain samples using transcriptomic, histological, and biochemical analyses. Unbiased proteomic screening was performed to identify the proteins that mediate cellular ABCA1 trafficking. We created ABCA1 knock out cell lines and mouse models to validate the role of ABCA1 in cholesterol-induced mTORC1 activation and senescence. Additionally, we used APOE4-TR mice and induced pluripotent stem cell (iPSC) models to explore cholesterol-ABCA1-senescence pathways.
Results
Transcriptomic profiling of the human dorsolateral prefrontal cortex from the Religious Order Study/Memory Aging Project (ROSMAP) cohort revealed the upregulation of cellular senescence transcriptome signatures in AD, which correlated with ABCA1 expression and oxysterol levels. Immunofluorescence and immunoblotting analyses confirmed increased lipofuscin-stained lipids and ABCA1 expression in AD brains and an association with mTOR phosphorylation. Discovery proteomics identified caveolin-1, a sensor of cellular cholesterol accumulation, as a key promoter of ABCA1 endolysosomal trafficking. Greater caveolin-1 expression was observed in APOE4-TR mouse models and AD human brains. Oxysterol induced mTORC1 activation and senescence were regulated by ABCA1 lysosomal trapping. Treatment of APOE4-TR mice with cyclodextrin reduced brain oxysterol levels, ABCA1 lysosome trapping, mTORC1 activation, and attenuated senescence and neuroinflammation markers. In human iPSC-derived astrocytes, the reduction of cholesterol by cyclodextrin attenuated inflammatory responses.
Conclusions
Oxysterol accumulation in APOE4 and AD induced ABCA1 and caveolin-1 expression, contributing to lysosomal dysfunction and increased cellular senescence markers. This study provides novel insights into how cholesterol metabolism accelerates features of brain cellular senescence pathway and identifies therapeutic targets to mitigate these processes.
Background: Surgical treatment of skull base pathologies is frequently discussed in the context endoscopic endonasal or transcranial approaches. Combined endoscopic and open approaches have been utilized in staged or sequential fashion, with the goal of reducing risk of postoperative cerebrospinal fluid leak, morbidity, wound infection/complication, and failure to achieve adequate reconstruction. However, few studies have described concurrent use of endoscopic endonasal and transcranial approaches to safely address complex skull base pathologies. Methods: We treated 13 patients with primary skull base tumors (sinonasal undifferentiated carcinoma/esthesioneuroblastoma), recurrent tumors, infection, and skull base defect/encephalocele. 8/13 patients had undergone prior endoscopic and/or open transcranial approaches for resection of their pathologies. 3/13 patients underwent radiation or chemotherapy and radiation prior to the combined approach. Results: The desired clinical outcome (i.e. gross total tumor resection, resolution of infection, and skull base resection/repair) was achieved in 12/13 cases. One case had subtotal resection (Simpson Grade III) of an olfactory groove meningioma. Post-operatively, there was one 30-day-mortality due to pulmonary infarction, one case with hydrocephalus requiring ventriculoperitoneal shunt placement and one flap infection due to postoperative cocaine use resulting in revisions and hospice. Importantly, no patients experienced postoperative CSF leaks, including those who underwent postoperative chemotherapy/radiation. Conclusion: This case series suggests that a concurrent combined endoscopic transcranial approach, in carefully selected patients, can treat a wide range of complex and recurrent skull base pathologies resistant to previous treatment, with a reasonable rate of post-operative wound/ leak complications.
- Alessio Cortellini
- Leonardo Brunetti
- Giuseppina Rita Di Fazio
- [...]
- Biagio Ricciuti
Background
Pembrolizumab monotherapy is an established front-line treatment for advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS)≥50%. However, real-world data on its long-term efficacy remains sparse.
Methods
This study assessed 5-year outcomes of first-line pembrolizumab monotherapy in a large, multicenter, real-world cohort of patients with advanced NSCLC and PD-L1 TPS≥50%, referred to as Pembro-real 5Y. Individual patient-level data (IPD) from the experimental arm of the KEYNOTE-024 trial were extracted (KN024 IPD cohort) to compare the long-term outcomes between the two cohorts. To further assess the reproducibility of clinical trial results, we reconstructed the “KN024 look-alike” cohort by excluding patients with an Eastern Cooperative Oncology Group-performance status (ECOG-PS)≥2, those requiring corticosteroids with doses ≥10 mg of prednisolone/equivalent, patients with positive/unknown epidermal growth factor receptor/anaplastic lymphoma kinase genotype, and those with pre-existing autoimmune disease. We additionally provided a hierarchical organization of determinants of long-term benefit through a conditional inference tree analysis.
Results
The study included 1050 patients from 61 institutions across 14 countries, with a median follow-up of 70.3 months. The 5-year survival rate was 26.9% (95% CI: 23.8% to 30.2%), and median OS was 21.8 months (95% CI: 19.1 to 25.7), while 32 (3.0%) patients who achieved a complete response remained progression-free at the data cut-off. The KN024 look-alike cohort had a 5-year survival rate of 29.3% (95% CI: 25.5% to 33.6%) and a median OS of 27.5 months (95% CI: 22.8 to 31.3). Neither the overall study population nor the KN024 look-alike cohort exhibited significantly different OS compared with the KN024 IPD cohort. By the data cut-off, 1015 patients (96.7%) had permanently discontinued treatment: 659 (64.9%) due to progressive disease, 156 (15.4%) due to toxicity, 77 (7.6%) due to treatment completion, and 106 (10.4%) due to other reasons. Overall, 222 participants (21.1%) were treated for a minimum period of 24 months, among them the 5-year survival rates were: 31.7%, 72.7%, 78.6%, 84.2% for patients who discontinued treatment due to progressive disease, toxicity, treatment completion, and other reasons, respectively.
Conclusion
This study provides valuable real-world evidence that confirms the long-term efficacy of pembrolizumab outside of clinical trials. Hierarchical organization indicates ECOG-PS, age and PD-L1-TPS as the most important predictors of 5-year survival, potentially informing clinical practice.
Background
Medication review is integral in the pharmacological management of older inpatients.
Objective
To assess the association of in-hospital medication changes with 28-day postdischarge clinical outcomes.
Methods
Retrospective cohort of 2000 inpatients aged ≥75 years. Medication changes included the number of increases (medications started or dose-increased) and decreases (medications stopped or dose-decreased) for (i) all medications, (ii) Drug Burden Index (DBI)–contributing medications and (iii) Beers Criteria 2015 medications (potentially inappropriate medications, PIMs). Changes also included differences in (i) the number of medications, (ii) the number of PIMs and (iii) DBI score, at discharge versus admission. Associations with clinical outcomes (28-day ED visit, readmission and mortality) were ascertained using logistic regression, adjusted for age, gender and principal diagnosis. For mortality, sensitivity analysis excluded end-of-life patients due to higher death risk. Patients were stratified into : (i) ≤4, (ii) 5–9 and (iii) ≥10 discharge medications.
Results
The mean age was 86 years (SD = 5.8), with 59.1% female. Medication changes reduced ED visits and readmission risk for patients prescribed five to nine discharge medications, with no associations in patients prescribed ≤4 and ≥ 10 medications. In the five to nine medications group, decreasing PIMs reduced risks of ED visit (adjusted odds ratio, aOR 0.55, 95% CI 0.34–0.91, P = .02) and readmission (aOR 0.62, 95% CI 0.38–0.99, P = .04). Decreasing DBI-contributing medications reduced readmission risk (aOR 0.71, 95% CI 0.51–0.99, P = .04). Differences in PIMs reduced ED visit risk (aOR 0.65, 95% CI 0.43–0.99, P = .04). There were no associations with mortality in sensitivity analyses in all groups.
Discussion
Medication changes were associated with reduced ED visits and readmission for patients prescribed five to nine discharge medications.
Importance
The integration of palliative care in neurology, or neuropalliative care, is an emerging area of practice focused on holistically improving quality of life and reducing the burden of suffering for people living with serious neurologic disease and their care partners. Major neurology and palliative care societies have recognized the need to advance primary and specialty palliative care services for people with neurologic disease. However, research to support this work is in its early stages.
Observations
The International Neuropalliative Care Society Research Committee convened an interdisciplinary panel of experts, including clinicians, scientists, people with neurologic disease, and care partners, to identify priority research areas for the advancement of neuropalliative care as a field. Three priority areas highlighted in this review include (1) patient- and care partner–centered symptoms and outcomes specific to neurologic illness and tools for their assessment, (2) development of effective neuropalliative care interventions and delivery models, and (3) methods to support the ability to foster, deliver, and measure goal-concordant care over time.
Conclusions and Relevance
This Special Communication outlines some of the most pressing neuropalliative care research needs, the advancement of which will best serve patients of all ages living with serious neurologic diseases and their care partners. Research funding mechanisms are needed to support and sustain impactful work in this field.
Total knee arthroplasty (TKA) is the gold standard for treatment of end stage knee osteoarthritis. Patellar resurfacing is an optional step in the procedure and remains a controversial topic of discussion. This retrospective study aims to assess the impact of over-resecting and under-resecting the patella during resurfacing on patient reported outcomes (PROMs) and range of motion (ROM) after surgery. 438 (92.2%) of 475 patients who underwent TKA between August 2017 and November 2019 at a single center by a single surgeon were included in the analysis. Patients were split into three study groups based on reconstructed patellar thickness; normal resection (NR) was defined as within 2 mm native thickness, over-resected (OR) was defined as ≤ -2 mm, and under-resected (UR) was defined as ≥ 2 mm. Statistical analyses included chi-squared test, mixed effect models, and cox proportional hazards models. There were 364, 41, 33 patients were in NR, OR, UR group respectively. The cohort mean age at time of surgery was 67.1 ± 9.1 and had mean length of follow-up of 2.1 ± 1.7 years with no difference among cohorts. Significant differences were found in gender (p<0.001) and BMI (p=0.0134) with UR having less males, OR having more males, and OR having lower BMI. At 6 months, the complete cohort ROM improved from 108.7 ± 14.4 degrees to 111 ± 11 degrees, objective Knee Society Score (KSS) increase from 15.4 ± 11.2 to 36.2 ± 12, functional KSS increase from 47.3 ± 18.9 to 65.6 ± 22.2, and knee injury and osteoarthritis outcome score increase from 46.1 ± 15 to 70.7 ± 15 with no significant differences among cohorts. There were no patellofemoral related complications. This study supports that while it is important to restore the anatomy in the anterior compartment of the knee, minor changes in patellar thickness from patellar resurfacing likely have minimal impact on outcomes for patients. Further studies with a larger sample size are necessary to further validate these findings.
Institution pages aggregate content on ResearchGate related to an institution. The members listed on this page have self-identified as being affiliated with this institution. Publications listed on this page were identified by our algorithms as relating to this institution. This page was not created or approved by the institution. If you represent an institution and have questions about these pages or wish to report inaccurate content, you can contact us here.
Information
Address
Chicago, United States
Website